Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPMX-T003 in Aggressive NK Cell Leukemia
NCT05863234Phase 2Recruiting
- Sponsor
- Hiroshima University Hospital
- Start
- Sep 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PPMX-T003 in aggressive NK-cell leukemia (ANKL), sponsored by Hiroshima University Hospital. Primary endpoint: Number of incidence of Adverse Events and Dose-Limiting Toxicities by PPMX-T003 repeated continuous intravenous administration (the first course) at 7 days. Started Sep 2023; status: recruiting.
02
Drugs
PPMX-T003
03
Conditions
aggressive NK-cell leukemia (ANKL)
Beyond the preview
Go deeper on NCT05863234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05863234.